Stock SOLARA SOLARA ACTIVE PHARMA SCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Solara Active Pharma Sciences Limited

Equities

SOLARA

INE624Z01016

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:43:54 2024-05-31 am EDT 		5-day change 1st Jan Change
30.95 INR -1.90% Intraday chart for Solara Active Pharma Sciences Limited -93.32% -91.43%
May. 29 Transcript : Solara Active Pharma Sciences Limited, Q4 2024 Earnings Call, May 29, 2024
May. 29 Solara Active Pharma Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 11,939 50,056 23,977 11,787 20,070 - -
Enterprise Value (EV) 1 11,939 53,088 23,977 11,787 13,353 20,070 20,070
P/E ratio 10.4 x 21.6 x -41.2 x -53.2 x - 48.1 x 21.3 x
Yield - 0.5% - - - 0.72% -
Capitalization / Revenue 0.9 x 3.1 x 1.89 x 0.82 x 1.04 x 1.24 x 1.13 x
EV / Revenue 0.9 x 3.1 x 1.89 x 0.82 x 1.04 x 1.24 x 1.13 x
EV / EBITDA 4.16 x 13 x 30 x 7.53 x 41.5 x 9.34 x 7.35 x
EV / FCF - -312 x -5.32 x 26.2 x 19.8 x 19.6 x -
FCF Yield - -0.32% -18.8% 3.81% 5.04% 5.1% -
Price to Book 1.1 x 3.15 x 1.57 x 0.79 x 1.28 x 1.77 x 1.45 x
Nbr of stocks (in thousands) 26,855 35,930 35,996 35,996 48,004 - -
Reference price 2 444.6 1,393 666.1 327.4 418.1 418.1 418.1
Announcement Date 5/7/20 5/6/21 4/29/22 5/12/23 5/29/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026
Net sales 1 13,218 16,169 12,683 14,438 12,889 16,206 17,813
EBITDA 1 2,870 3,859 799.7 1,565 322 2,149 2,731
EBIT 1 - 2,772 -323.5 452.7 -1,950 1,280 1,605
Operating Margin - 17.14% -2.55% 3.14% -15.13% 7.9% 9.01%
Earnings before Tax (EBT) 1 1,149 2,215 -911 -448.1 -4,884 418 943
Net income 1 1,146 2,214 -581.5 -221.7 -5,674 417 942
Net margin 8.67% 13.69% -4.58% -1.54% -44.02% 2.57% 5.29%
EPS 42.82 64.52 -16.18 -6.160 - 8.700 19.60
Free Cash Flow 1 - -160.5 -4,506 449.4 1,012 1,024 -
FCF margin - -0.99% -35.53% 3.11% 7.07% 6.32% -
FCF Conversion (EBITDA) - - - 28.72% 220% 47.65% -
FCF Conversion (Net income) - - - - - 245.56% -
Dividend per Share 2 - 7.000 - - - 3.000 -
Announcement Date 5/7/20 5/6/21 4/29/22 5/12/23 5/29/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 4,016 1,003 3,608 3,301 3,384 3,948 3,806 3,523 4,252 2,487 2,994
EBITDA 1 718.6 -968.4 135.3 125.5 275.7 450 474.9 191.2 376.3 -1,617 378
EBIT - - - - - - - - - - -
Operating Margin - - - - - - - - - - -
Earnings before Tax (EBT) 1 296.8 -1,399 -310 -311 -193 5.5 50.4 -293.6 -170.6 -2,753 -1,667
Net income 1 297.1 -1,399 18.8 -164.3 -99.6 4.5 37.7 -195.5 -171.6 -2,753 -2,553
Net margin 7.4% -139.4% 0.52% -4.98% -2.94% 0.11% 0.99% -5.55% -4.04% -110.7% -85.28%
EPS - - - - - - - - - - -
Dividend per Share - - - - - - - - - - -
Announcement Date 11/11/21 2/9/22 4/29/22 8/4/22 11/9/22 1/25/23 5/12/23 8/14/23 11/14/23 2/14/24 5/29/24
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026
Net Debt - 3,032 - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - 0.7858 x - - - - -
Free Cash Flow 1 - -161 -4,507 449 1,012 1,024 -
ROE (net income / shareholders' equity) 10.6% 16.6% -14.9% -1.47% -18.9% 4% 7.5%
ROA (Net income/ Total Assets) - 9.29% - - - - -
Assets 1 - 23,835 - - - - -
Book Value Per Share 2 404.0 442.0 424.0 417.0 328.0 236.0 289.0
Cash Flow per Share - - - - - - -
Capex 1 - 1,745 2,086 1,113 1,000 500 500
Capex / Sales - 10.79% 16.45% 7.71% 6.99% 3.09% 2.81%
Announcement Date 5/7/20 5/6/21 4/29/22 5/12/23 5/29/24 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Solara Active Pharma Sciences Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
418.1 INR
Average target price
347 INR
Spread / Average Target
-17.01%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SOLARA ACTIVE PHARMA SCIENCES LIMITED Stock Solara Active Pharma Sciences Limited
-91.43% 240M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
PFIZER, INC. Stock Pfizer, Inc.
-0.45% 162B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SOLARA Stock
  4. Financials Solara Active Pharma Sciences Limited